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Adenosine A2A Receptor Antagonists Exert
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Objective: To investigate whether the motor and neuroprotective effects of adenosine A2A receptor (A2AR) antagonists are
mediated by distinct cell types in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson’s disease.
Methods: We used the forebrain A2AR knock-out mice coupled with flow cytometric analyses and intracerebroventricular
injection to determine the contribution of A2ARs in forebrain neurons and glial cells to A2AR antagonist-mediated motor and
neuroprotective effects.
Results: The selective deletion of A2ARs in forebrain neurons abolished the motor stimulant effects of the A2AR antagonist
KW-6002 but did not affect acute MPTP neurotoxicity. Intracerebroventricular administration of KW-6002 into forebrain
A2AR knock-out mice reinstated protection against acute MPTP-induced dopaminergic neurotoxicity and attenuated MPTP-
induced striatal microglial and astroglial activation.
Interpretation: A2AR activity in forebrain neurons is critical to the control of motor activity, whereas brain cells other than
forebrain neurons (likely glial cells) are important components for protection against acute MPTP toxicity.
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In recent years, adenosine A2A receptors (A2ARs) have
emerged as a leading nondopaminergic therapeutic tar-
get in Parkinson’s disease (PD).1–3 This excitement is
primarily due to two lines of recent experimental and
clinical evidence. First, selective A2AR antagonists such
as KW-6002 have been shown to stimulate motor ac-
tivity, alone or in combination with L-dopa, to provide
symptomatic relief in PD as evidenced in rodents,4,5
nonhuman primates,6,7 and recent clinical studies.8,9
Second, epidemiological studies show an inverse rela-
tion between caffeine consumption and the risk for de-
velopment of PD,10,11 and animal studies show that
A2ARs contribute to the degeneration of nigrostriatal
dopaminergic neurons,12,13 raising the prospect that
A2AR antagonists may also represent a neuroprotective
strategy for PD. Thus, the use of A2AR antagonists
could constitute a significant improvement in PD ther-
apy compared with the current L-dopa monotherapy,
which does not slow down dopaminergic neurodegen-
eration.14
The dual motor/protective benefit of A2AR antago-
nists for PD patients raises an important question: Is
the motor stimulation and neuroprotection exerted by
A2AR antagonists mediated by distinct or common cel-
lular mechanisms? Although the antagonistic interac-
tion between A2AR and D2 dopamine receptors in
striatopallidal neurons is considered the molecular basis
for A2AR-mediated motor stimulation,
15 the mecha-
nism by which A2AR inactivation attenuates dopami-
nergic degeneration is largely unknown. Given the pre-
dominant expression of A2ARs in the striatal neurons,
A2ARs in forebrain neurons are believed to be respon-
sible not only for motor control but also for the neu-
roprotection afforded by A2AR antagonists. In addi-
tion, mechanisms involving various cellular and
molecular elements (including dopaminergic neurons,
microglial cells, vesicular monoamine transporter, and
monoamine oxidase-B) have also been suggested.16 The
dissection of the cellular mechanism underlying motor
stimulation and neuroprotection by A2AR antagonists
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may provide a basis for achieving the dual benefits by
targeting A2ARs in distinct cells.
The key to addressing this important issue is to dis-
tinguish the contributions of A2ARs in different cell
types to motor stimulation and neuroprotection in PD
models. However, current pharmacological and global
genetic knock-out (KO) approaches to A2ARs are not
adequate to discern the specific actions of A2ARs in dif-
ferent cell types. To circumvent this limitation, we de-
veloped forebrain neuron-specific A2AR KO mice (fb-
A2AR KO) by crossing “floxed” A2AR mice with the
calmodulin-dependent protein kinase II  subunit
(CaMKII)-Cre transgenic line.17 Using this novel
forebrain A2AR KO line together with pharmacological
approaches, we provide the first direct evidence that
A2AR antagonists exert their motor and neuroprotec-
tive benefits by targeting forebrain neurons and brain
cells other than forebrain neurons (such as glial cells),
respectively, in the MPTP model of PD.
Materials and Methods
Transgenic Mice
The animals were handled in accordance with the guidelines
and protocols approved by the Institutional Animal Care and
Use Committee at Boston University School of Medicine.
The generation and characterization of the global A2AR KO
mice (gb-A2AR KO) of congenic C57BL/6 genetic back-
ground (N10) have been described previously.18 The gener-
ation and genotyping of the forebrain A2AR KO mice (fb-
A2AR KO) of near congenic C57BL/6 background (N6) have
also been described recently.17 Both Cre()A2AR
flox/
and Cre()A2AR
flox/ were used as wild-type (WT) control
(referred to as fb-WT) to compare with fb-A2AR KO
[Cre()A2AR
flox/]. In pilot studies, we found that
both WT control animals [Cre()A2AR
flox/ and
Cre()A2AR
flox/] produce similar behavioral (locomotor)
and neurochemical (striatal dopamine contents) effects. All an-
imals in this study were 90 days or older due to the
CaMKII-Cre–mediated A2AR deletion time course.
Locomotor Activity and Drugs
Horizontal locomotor activity was assessed in standard activ-
ity cages as described previously.12,18 All mice were habitu-
ated to the testing environment, and basal locomotion was
recorded before and after drug treatments. Mice were mon-
itored during the light or dark phase of the light/dark cycle
to obtain low and high baseline locomotor activity when
studying A2AR antagonists and A2AR agonists. KW-6002
19
was dissolved in vehicle (15% DMSO, 15% castor oil, and
70%H2O) and CGS21680 (Tocris, Ellisville, MO) was dis-
solved in saline.
In Situ Hybridization
Postfixed brain sections were hybridized with 0.4nM 35S-
oligonucleotide probe (approximately 1.5  106cpm per
80l per slide) at 37°C overnight and washed at high
strength as described previously.20 The A2AR oligonucleotide
probe was mapped at 51 to 95bp of the A2AR complemen-
tary DNA sequence (NM_009630).
Membrane Binding Assay
Total membranes or Percoll-purified synaptosomal mem-
brane preparations from frontal cerebral cortex, striatum, or
hippocampus were prepared as described previously.21 Mem-
brane preparations were incubated with 3H-SCH58261 (spe-
cific activity of 77Ci/mmol; a gift from Dr Ennio Ongini,
Shering-Plough, Italy) for 1 hour, as described previously.21
Xanthine amine conger (1M) was used to assess nonspecific
binding.
Western Blot Analysis
Total membrane preparations of striatum were separated by
sodium dodecyl sulfate polyacrylamide gel electrophoresis,
transferred, and incubated with a mouse anti-A2AR antibody
(1:1,000; Upstate Biotechnology, Lake Placid, NY) as de-
scribed previously. The membranes were developed with en-
hanced chemifluorescence and quantification achieved with
the Quantity One System (Bio-Rad, Richmond, CA).21
Immunohistochemistry
Perfused brain were sectioned coronally (30m), and immu-
nohistochemistry was performed as described previously.18,22
In brief, the sections were incubated with an anti–mouse
A2AR (1:500; Upstate Biotechnology) and developed with
peroxidase-diaminobenzidine tetrahydrochloride solution
(Vector Laboratories, Burlingame, CA). Sections from mid-
brain were stained with anti–mouse tyrosine hydroxylase (1:
200; Chemicon International, Temecula, CA). The tyrosine
hydroxylase–positive nigral cells were counted manually by
an observer blind to the treatment. The average cell counts
of two sections from each animal were used to calculate cell
numbers. To further evaluate the colocalization of A2ARs in
neuronal and glial cells in fb-A2AR-KO, we treated the mice
with MPTP (40mg/kg intraperitoneally [ip]) 2 days later,
brains were sectioned through striatum, and we incubated
the section with mouse anti-A2AR (1:500 dilution; Upstate
Biotechnology) in combination with either rabbit anti–-
tubulin III (1:1,000; Covance, Princeton, New Jersey), anti-
CD11b (1:100; Serotec, Bicester, United Kingdom), or anti–
glial fibrillary acidic protein (GFAP; 1:500; Dako,
Carpinteria, CA), followed by incubation with an anti–
mouse IgG conjugated with Alexa Fluor 488 and an anti–
rabbit IgG conjugated with Alexa Fluor 594 (1:200; Molec-
ular Probes, Eugene, OR). Nuclei were stained with Hoechst
33342 (2g/ml). The brain sections were analyzed in a laser-
scanning confocal microscope (LSM 510 META; Zeiss,
Thornwood, NY).
Fluorescent Activated Cell Sorting/Flow
Cytometry Analysis
Brain tissue of different regions was cut into small pieces,
treated briefly with 0.025% trypsin-EDTA (Invitrogen, La
Jolla, CA) at room temperature, and filtered through a
70m cell constrainer (BD Biosciences, San Jose, CA) to
obtain single-cell suspension. The cells were then incubated
with anti–mouse -tubulin III (1:50; Sigma-Aldrich, St.
Louis, MO), Fluor 488–conjugated anti–mouse GFAP (1:
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100; Molecular Probes) or Phycoerythrin-conjugated anti–
mouse CD11b (1:100; BD Biosciences). The cells were per-
meabilized with 0.5% saponin for 15 minutes on ice before
labeling with the anti–-tubulin III and anti-GFAP antibod-
ies, followed by an extended wash procedure (4 washes of 10
minutes each) to reduce the background staining. The cells
were either separated using a fluorescent activated cell sorter
(MoFlo; Dako) for genotyping and membrane binding assay
or scanned for fluorescence intensity on a flow cytometry
scan (BD Biosciences). The genomic DNA was extracted
from the sorted cells to detect Cre-mediated A2AR gene de-
letion by polymerase chain reaction. For the A2AR binding
study, about one million sorted CD11b cells isolated from
the cerebral cortex and hippocampus of three to four fb-
A2AR KO or fb-WT mice were pooled to determine the
3H-
SCH58261 binding in these cells.
MPTP Treatment Paradigms and
Catecholamine Measurements
Three MPTP treatment paradigms were used in this study.
First is the multiple-injection paradigm: Mice received three
intraperitoneal injections of 20mg/kg MPTP at 2-hour inter-
vals.12 Second is the single-injection paradigm: A single in-
jection paradigm of 40mg/kg MPTP was used to further val-
idate the three-injection paradigm and to accommodate the
intracerebroventricular injection paradigm of the A2AR an-
tagonist KW-6002. KW-6002 (10g/2l/brain) was injected
intracerebroventricularly (ICV) using a stereotaxic apparatus
(anterior 1.0mm, depth 2.0mm, and lateral 0.5mm,
relative to Bregma). Ten minutes later, the mice were admin-
istered a single injection (IP) of 40mg/kg MPTP. Third is
the subchronic treatment paradigm: Daily injection of
MPTP (30mg/kg IP) for 5 days as described previously5 to
deplete dopamine. Thirty minutes after the last injection of
MPTP (day 5), the mice were treated with KW-6002
(3mg/kg IP) and their locomotor activities were recorded for
120 minutes. MPTP-induced neurodegeneration was as-
sessed 7 days after the last injection. Striatal dopamine levels
were assessed by standard reverse-phase high-pressure liquid
chromatography with electrochemical detection.12
Statistical Analysis
Statistical comparisons were performed by unpaired Stu-
dent’s t test or one-way analysis of variance followed by Bon-
ferroni post hoc comparisons. Otherwise, nonparametric
Mann–Whitney U test or Kruskal–Wallis H test was used.
For behavioral analysis, we performed two-way analysis of
variance for repeated measurements followed by Bonferroni
post hoc comparison for the effects of genotype, drug treat-
ment, and their interaction.
Results
Genetic and Biochemical Characterization of Forebrain
Adenosine A2A Receptor Knock-out Mice
The deletion of the A2AR gene mediated by CaMKII-
Cre was detected only in Cre() mice specifically in
forebrain regions (Fig 1A). Analyses by binding assays
(see Fig 1B), in situ hybridization (data not shown),
and Western blotting (see Fig 1C) show that the A2AR
mRNA, and protein levels were abolished to the back-
ground levels observed in the gb-A2AR KO mice. To
characterize the specificity of A2AR gene deletion at the
cellular level, we isolated neurons (-tubulin III), mi-
croglia (CD11b), and astrocytes (GFAP) from fb-
A2AR KO and fb-WT mice (Cre()flox
/) by fluo-
rescent activated cell sorting. The polymerase chain
reaction and binding analyses of the sorted cells indi-
cates that in the fb-A2AR KO mice, the deletion of
A2AR gene (at genomic DNA and protein levels) is
neuron specific (Figs 2A, B) because neither the A2AR
gene nor the A2AR protein density on CD11b
 (ie,
microglial) cells are affected as indicated by polymerase
chain reaction (see Fig 2A) and binding (see Fig 2B)
assays. Furthermore, double immunohistochemistry
showed that the induction of A2AR expression by
MPTP treatment was colocalized with the expression
of astroglial (ie, GFAP) and microglial markers (ie,
CD11b) in striatum of fb-A2AR KO (see Fig 2C) af-
ter the acute MPTP treatment. As expected, no A2AR
immunoreactivity was detected in striatal neurons (ie,
tubulin-III) of fb-A2AR KO mice (see Fig 2C). To-
gether, these data demonstrate that the newly devel-
oped fb-A2AR KO line depleted A2AR messenger RNA
and protein in forebrain neurons to levels similar to
those of the gb-A2AR KO mice, but A2AR gene and
protein density in glial cells remain intact in fb-A2AR
KO mice.
Selective Deletion of Adenosine A2A Receptors in
Forebrain Neurons Abolishes the Motor Effects of
Adenosine A2A Receptor Antagonists and Agonists
We evaluated the effect of the genetic deletion of
A2ARs in forebrain neurons on the A2AR modulation
of motor activity. The selective A2AR agonist
CGS21680 (0.05mg/kg IP) produced significant motor
depression in fb-WT mice that lasted for more than 3
hours (Fig 3A). This motor depressant effect was par-
tially attenuated in fb-A2AR KO mice (see Fig 3A).
Next, we assessed the motor stimulant effect of the se-
lective A2AR antagonist KW-6002 and of the nonselec-
tive antagonist caffeine in fb-A2AR KO mice. KW-
6002 (3mg/kg) produced a strong motor stimulation in
fb-WT mice, which was abolished in fb-A2AR KO
mice (see Fig 3B). The motor stimulant effect induced
by caffeine (10mg/kg) was also largely attenuated in
fb-A2AR KO mice (see Fig 3C). Thus, A2ARs in fore-
brain neurons are critical for the A2AR-mediated motor
effects. We next investigated the A2AR-mediated motor
effects in dopamine-depleted conditions by testing the
effect of KW-6002 after a subchronic MPTP treatment
paradigm. The locomotor activity was reduced by this
subchronic treatment to less then 10% of baseline (be-
fore the MPTP treatment). On the last day of treat-
ment, KW-6002 (3mg/kg IP) administered 30 minutes
after the last MPTP injection significantly increased
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motor activity in MPTP-intoxicated fb-WT mice, but
not in MPTP-intoxicated fb-A2AR KO mice (see Fig
3D). Therefore, A2AR antagonists act at forebrain neu-
rons to stimulate motor activity in both normal dopa-
mine and dopamine-depleted conditions.
Selective Deletion of the Adenosine A2A Receptor in
Forebrain Neurons Does Not Confer Neuroprotection
against Acute MPTP-Induced Toxicity
We next examined the contribution of A2ARs in fore-
brain neurons to the neuroprotection in the MPTP
model. Consistent with our previous study,12 residual
striatal dopamine content of gb-A2AR KO mice
(23.0  7.4pmol/mg tissue) was significantly greater
than that of gb-WT littermates (7.9  1.6pmol/mg
tissue) after the acute MPTP treatment (multiple injec-
tion paradigm, p  0.05), confirming the neuroprotec-
tion afforded by global deletion of A2ARs. In contrast
with gb-A2AR KO mice, the residual striatal dopamine
levels were indistinguishable between fb-A2AR KO
mice (5.9  1.8pmol/mg tissue) and fb-WT litter-
mates (6.2  1.0pmol/mg tissue) after MPTP treat-
ment (p 	 0.05; Fig 4). The single-injection paradigm
of acute MPTP treatment produced results similar to
the multiple-injection paradigm (Fig 5A). This indi-
cates that the selectives deletion of A2ARs in forebrain
neurons is not sufficient to confer neuroprotection
against MPTP-induced dopaminergic toxicity.
Intracerebroventricular Administration of the
Adenosine A2A Receptor Antagonist KW-6002 into
fb-A2A Receptor Knock-out Mice Confers Protection
against Acute MPTP-Induced Neurodegeneration
We then determined whether A2ARs located in brain
cells other than forebrain neurons contribute to neuro-
protection by testing the effect of ICV injection of
KW-6002 on MPTP-induced neurotoxicity in fb-A2AR
KO mice. KW-6002 (ICV) was administered into fb-
A2AR KO mice or fb-WT littermates 10 minutes be-
fore a single injection of MPTP (40mg/kg IP). MPTP
produced a significant reduction of striatal dopamine
content both in fb-A2AR KO mice and fb-WT litter-
Fig 1. Characterization of the forebrain adenosine A2A receptor (A2AR) knock-out (KO) mice. Homozygous “floxed” (A2AR
flox/)
mice (F5 generation in a mixed 129-Steel and C57BL/6 genetic background) were crossbred with calmodulin-dependent protein
kinase II  subunit (CaMKII)-Cre transgenic mice (L7ag13, in a C57BL/6 background) expressing the Cre recombinase under
the control of the CaMKII gene promoter in forebrain neurons,37 to generate heterozygous fb-A2AR KO mice [CaMKII-
Cre()A2AR
flox/]. (A) Forebrain-specific, Cre-mediated DNA recombination, as detected by genomic polymerase chain reaction
(PCR) analysis, in the mouse tissues from eight brain regions and six peripheral organs that were dissected from fb-A2AR KO mice
[Cre()A2AR
flox/] or fb-A2AR wild-type (WT) littermates [Cre()A2AR
flox/] and genomic DNA were isolated. Cre-mediated
A2AR gene deletion (“fb-KO” band) was detected only in the fb-A2AR KO mice but not in fb-WT littermates. Furthermore, Cre-
mediated A2AR gene deletion was detected specifically in forebrain regions, including olfactory bulb (OB), striatum (ST), hippocam-
pus (HIP), cerebral cortex (CTX) and hypothalamus (HYP), but not in the cerebellum (CB), brainstem (BS), midbrain (MD; left
panel), or in the six peripheral organs, including thymus (THY), heart (HRT), lung (LG), kidney (KID), liver (LIV), and spleen
(SPL). (B) Quantitative analysis of 3H-SCH58261 binding densities in whole-membrane preparations of the cerebral cortex, hip-
pocampus, and striatum from gb-A2AR KO mice, fb-A2AR KO mice, and their corresponding WT littermates. (C) Western blot
analysis of A2AR protein levels in the striata from gb-A2AR KO mice (lane 1 from left), fb-A2AR KO mice (lane 3), and their cor-
responding WT littermates (lanes 2 and 4).
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mates pretreated with vehicle (see Fig 5B). Pretreat-
ment with KW-6002 protected against MPTP toxicity
in fb-A2AR KO mice to an extent similar to that ob-
served in KW-6002 pretreated fb-WT littermates.
Fig 2. Selective deletion of the adenosine A2A receptor (A2AR;
gene and proteins) in forebrain neurons and selective induc-
tion of A2AR (protein) by acute 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) treatment in striatal glial cells in
fb-A2AR knock-out (KO) mice. (A) Polymerase chain reaction
(PCR) genotyping of Cre-mediated DNA recombination
(where the presence of the “fb-KO” band indicates Cre-
mediated A2AR gene deletion) in fluorescent activated cell
sorted (FACS) striatal neurons (-tubulin III), microglia
(CD11b, left panel), or astrocytes (glial fibrillary acidic pro-
tein–positive [GFAP], right panel) collected from both fb-
A2AR KO and fb-wild-type (WT) mice. (B) Quantitative
analysis of 3H-SCH58261 binding densities in sorted
CD11b cells from cerebral cortex and hippocampus of gb-
A2AR KO, fb-A2AR KO, and WT mice (fb-WT). gb-KO 

global A2AR KO mice; fb-A2AR KO 
 forebrain A2AR KO;
gb-WT 
 global A2AR wild-type mice; fb-WT 
 forebrain
A2AR wild-type mice. (C) Selective colocalization of A2AR and
glial (GFAP and CD11b) but not neuronal (-tubulin
III) markers in striatum after the acute MPTP treatment,
evaluated by confocal microscopy. -Tubulin III (red),
GFAP (red), and CD11b cells (left column) were double-
labeled with A2AR (green) (middle column) to yield merged
images (yellow) (right column). Nuclei were labeled with
Hoechst 33342 (light blue) and shown in the merged micro-
graphs. Scale bars 
 20m. (A, B) Data are presented as
means  standard error (n 
 three to six samples/group, with
CD11b cells isolated from forebrain of three to four mice
being pooled for each sample).
Fig 3. Selective inactivation of adenosine A2A receptors
(A2ARs) in forebrain neurons completely abolishes motor
stimulant effects of KW-6002 and partially abolishes the
motor depressant effect of CGS21680. (A) CGS21680-
induced motor depression was attenuated in fb-A2AR knock-
out (KO) mice: fb-A2AR KO mice (n 
 15; squares) and
fb-wild-type (fb-WT; circles) littermates (n 
 13) were
treated with CGS21680 (0.05mg/kg intraperitoneally [IP])
and monitored for their locomotor activities using an auto-
matic recording system during the dark phases (closed bar)
of the light/dark cycle for 8 hours (see Materials and Meth-
ods). (B) KW-6002–induced motor stimulation in fb-WT
but not in fb-A2AR KO mice with normal dopamine neuro-
transmission (n 
 8–9). Arrow indicates the injection
point. (C) Caffeine-induced motor activity in fb-WT but not
fb-A2AR KO mice under normal dopamine neurotransmission
(n 
 6–8). (D) KW-6002-induced locomotor activity in
fb-WT and but not in fb-A2AR KO mice with depleted do-
pamine transmission induced with subchronic treatment
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): fb-
A2AR KO and WT mice (n 
 8) were treated with MPTP
(30mg/kg IP) daily for 5 days. After the fifth dose of MPTP,
both fb-A2AR KO and fb-WT mice were recorded for basal
locomotor activity for 30 minutes before they were treated with
KW-6002 (3mg/kg), and recorded of their motor activities for
additional 120 minutes thereafter (n 
 8). *p  0.05 com-
paring fb-A2AR KO mice with their fb-WT littermates, two-
way analysis of variance followed by Bonferroni test.
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KW-6002 pretreatment in fb-A2AR KO and fb-WT
mice increased residual dopamine contents by twofold
compared with the vehicle-pretreated groups (see Fig
5B; p  0.01). Thus, KW-6002 protects against acute
MPTP neurotoxicity by blocking A2ARs located in
brain cells other than forebrain neurons.
MPTP treatment (single-injection paradigm) also
significantly reduced the number of tyrosine hydroxy-
lase–positive cells in substantia nigra (SN) (p  0.01;
see Fig 5C). This reduction was largely attenuated by
pretreatment with KW-6002 (ICV) compared with the
vehicle-pretreated mice (p  0.01; see Fig 5C). This
result suggests that A2AR antagonists acting at nonfore-
brain cells provide not only functional protection
against striatal dopamine depletion but also attenuate
the degeneration of dopaminergic neurons in the SN.
Intracerebroventricular Injection of KW-6002
Attenuates Striatal Microglial and
Astroglial Activation
Having established that KW-6002 affords neuroprotec-
tion by blocking A2ARs located in brain cells other
than forebrain neurons, we investigated the influence
of KW-6002 on glial activation in the MPTP model.
Because of the elusive nature of the functional charac-
terization of glia in the brain, we used flow cytometry
analysis to quantify striatal CD11b cells (a microglial
marker) and GFAP cells (an astrocytic marker) in
MPTP-intoxicated mice. C57BL/6 WT mice were pre-
treated with vehicle or KW-6002 (ICV) followed by
MPTP treatment (single-injection paradigm), and the
striatal cells were prepared 48 hours thereafter. MPTP
treatment markedly increased the overall expression of
CD11b and GFAP (per 5  105 total events), as the
total CD11b and GFAP cell numbers increased by
2- and 1.3-fold, respectively, compared with the saline-
treated mice (Fig 6; p  0.01). The most significant
increase in CD11b cells was seen in the subpopula-
tion with large cell size (see Fig 6B) by more than five-
fold compared with the saline-treated mice. Impor-
tantly, KW-6002 attenuated the increase in CD11b
cells induced by MPTP most significantly in the sub-
Fig 5. Intracerebroventricular (ICV) injection of KW-6002
protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) neurotoxicity. Forebrain adenosine A2A receptor (A2AR)
knock-out (KO) mice and fb-wild-type (WT) littermates re-
ceived an ICV injection of KW-6002 (10g/2l/brain) 10
minutes before a single dose of MPTP (40mg/kg intraperitone-
ally [IP]). (A) Striatal dopamine contents in fb-A2AR KO mice
and fb-WT mice treated with single dose of MPTP (40mg/kg
IP; black bars or saline; white bars) White bars represent sa-
line treatment. (B) Pretreatment with KW-6002 attenuated the
MPTP-induced depletion of striatal dopamine contents in both
fb-A2AR KO and fb-WT mice compared with the vehicle-
pretreated counterparts. Black bars represent MPTP plus vehi-
cle; striped bars represent MPTP plus KW-6002. *p  0.05, t
test compared with the vehicle-pretreated group, n 
 6. (C)
C57BL/6 WT mice were pretreated with KW-6002 (10g/
brain) or vehicle (ICV) before intoxicated with the single dose
of MPTP (40mg/kg IP). The numbers of substantia nigra ty-
rosine hydroxylase–positive (TH) cells (right panel) were
counted 7 days after MPTP treatment. *#p  0.05, Bonferroni
test; KW-6002–pretreated, MPTP-intoxicated group compared
with vehicle-pretreated MPTP-intoxicated group, and MPTP-
intoxicated group compared with group without MPTP intoxi-
cation (normal control), respectively. Representative microphoto-
graphic images (magnification 2) from each group are showed
in the left panel.
Fig 4. Selective inactivation of adenosine A2A receptors
(A2ARs) in forebrain neurons does not confer neuroprotection
against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
neurotoxicity. Global A2AR knock-out (KO) and fb-A2AR KO
mice and corresponding wild-type (WT) littermates (gb-WT
and fb-WT) were treated with MPTP (20mg/kg three times
intraperitoneally at 2-hour interval). Seven days later, striatal
dopamine contents were determined by high-pressure liquid
chromatography (HPLC). The striatal dopamine contents were
significantly greater in gb-KO mice compared with gb-WT
littermates (p  0.05, Mann–Whitney U test). Striatal dopa-
mine contents were not significantly different between fb-A2AR
KO mice and fb-WT littermates after MPTP treatment (p 	
0.05, Mann–Whitney U test). n 
 6–7 for the MPTP-
treated group (black bars); n 
 3 for the saline-treated group
(white bars). p  0.05 compared to those treated with
saline *p  0.05 compared with WT littermates
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population of CD11b cells with large size (see Fig
6B; p  0.01) compared with the vehicle-pretreated
mice. KW-6002 pretreatment also significantly attenu-
ated the increase of striatal GFAP cell number in-
duced by MPTP treatment (see Fig 6C; p  0.05)
compared with vehicle-pretreated mice. This attenua-
tion of GFAP cell number was observed in both
large and small cell size subpopulations (see Fig 6D).
These results suggest that KW-6002 can protect against
MPTP neurotoxicity by attenuating MPTP-induced
microglial and astroglial activation in vivo.
Discussion
The major novel finding of this study is the unambig-
uous demonstration that A2AR antagonists stimulate
motor activity and protect against dopaminergic neu-
rotoxicity by distinct cellular mechanisms in the MPTP
model of PD. The finding is strengthened by the de-
velopment of fb-A2AR KO mice with the forebrain re-
gional and neuronal specificity, and near completeness
of the adenosine A2AR gene deletion. The A2AR-
mediated locomotor control was lost in mice lacking
the A2AR in forebrain neurons, but A2AR antagonists
were still able to afford neuroprotection in these mice.
We also found that the neuroprotection afforded by
A2AR blockade against MPTP-induces toxicity corre-
lates with the modulation of the activation of micro-
glial and astroglial cells in the striatum.
Deletion of A2ARs in forebrain neurons abolished
the motor stimulant effects of KW-6002, both in nor-
mal and dopamine-depleted conditions (see Fig 3).
The A2AR antagonist remained effective in producing
motor stimulation in the fb-WT mice in either normal
or dopamine-depleted conditions (see Fig 3). It should
also be noted that while KW-6002-induced motor
stimulation is completely abolished in fb-A2AR KO
mice, the motor-stimulant effect of caffeine and the de-
pressant effect of CGS21680 were only partially atten-
uated, suggesting the possible contributions from other
targets. The finding that forebrain neurons are required
for the motor effects of A2AR antagonists has impor-
tant implications for the therapeutic development of
A2AR antagonists for PD patients. Patients with ad-
vanced PD (where neuroprotective strategies may not
be effective because more than 90% of the dopaminer-
gic neurons have degenerated) can still benefit from the
motor stimulant effect of A2AR antagonists because
their molecular targets (ie, forebrain/striatal neurons)
remain largely intact.
The lack of an effect on A2AR-mediated neuropro-
tection against acute MPTP in forebrain A2AR-KO
mice suggests that the neuroprotection afforded by
Fig 6. Intracerebroventricular (ICV) injection of KW-6002 attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)–in-
duced striatal glial activation assessed by flow cytometry analysis. Wild-type C57BL/6 mice were pretreated with vehicle or KW-
6002 (10g/brain ICV) 10 minutes before the single injection of MPTP (40mg/kg intraperitoneally). The striatum was dissected
out at 48 hours after the MPTP treatment. The striata were acutely dissociated and labeled with anti-CD11b or anti–glial fibril-
lary acidic protein (GFAP) antibody, and analyzed with a fluorescent activated cell sorting (FACS) scan (see Materials and Meth-
ods). Activated microglia and astrocytes were expressed as CD11b (A, B) or GFAP (C, D) per 500,000 total scanning events
and further separated according to cell size. The y-axis indicates the florescence intensity, and the x-axis indicates the cell size (small
vs large cells). #p  0.01, Bonferroni test, compared with the saline-treated group; *p  0.05 compared with the vehicle-pretreated
mice. n 
 4–6/group.
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global A2AR inactivation is likely due to A2ARs located
in different cell types, such as nonforebrain neurons or
glial cells where A2AR have also argued to be locat-
ed.23,24 KW-6002 administration (ICV) provided neu-
roprotection against acute MPTP-induced neurotoxic-
ity in fb-A2AR KO mice, indicating that A2ARs in
brain cells other than forebrain neurons are responsible
for the observed neuroprotection. This is further sup-
ported by the selective induction of the A2AR in glial
cells (both microglial and astrocytes) in striatum of fb-
A2AR KO after the acute MPTP treatment. As ex-
pected, there was no A2AR immunoreactivity in the
striatal neurons of fb-A2AR KO mice. The A2AR mod-
ulation of glial function is an important cellular mech-
anism by which A2AR inactivation could confer neuro-
protection against dopaminergic neurotoxicity, as
suggested by several findings: A reactive microglial re-
sponse occurs in the vicinity of dying dopaminergic
neurons in human postmortem SN from PD, MPTP-
intoxicated patients,25–27 and animal models of
PD28,29; the action of minocycline, which inhibits mi-
croglia function, attenuates degeneration of nigrostria-
tal dopaminergic neurons in animal models of PD28;
and KW-6002 attenuates MPTP neurotoxicity and mi-
croglial activation in the SN.30 Furthermore, the acti-
vation of A2ARs in astroglial cells has been implicated
in excitotoxicity through its effects on the release and
uptake of glutamate from astrocytes.31,32
Microglial activation induced by MPTP was attenu-
ated by the A2AR antagonist KW-6002 (see Fig 6),
demonstrating the involvement of A2ARs in the mod-
ulation of microglial function in the MPTP model.
Furthermore, flow cytometry analysis, a unique ex vivo
assessment of the functional status of microglial and
astroglial cells, showed that the reduction in microglial
activation by KW-6002 pretreatment is largely seen in
the subpopulation of microglia with large cell body
size, which indicates a fully activated status (see Figs
6A, B, specifically “large” subpopulation in A). This
result suggests that A2AR antagonists may mainly at-
tenuate the progression of microglial activation to fully
activated status (rather than the initiation), because the
large size subpopulation of MPTP-activated microglial
cells are selectively attenuated by KW-6002, suggesting
an important role for A2AR in regulating overactivation
of microglia. This was further supported by immuno-
histochemistry demonstration that A2AR immunoreac-
tivity was found to be colocated with activated micro-
glia (ie, CD11 elements with the morphology of
activated microglia). KW-6002 was also able to atten-
uate MPTP-induced astroglial activation in striatum,
but in contrast with the effect on microglial activation,
both large and small cell size subpopulations of astro-
glia were affected (see Figs 6C, D). This effect on the
astroglial response may indicate that the A2AR antago-
nist can reduce astroglial activation in different stages
of activity, unlike the effect on microglia. Again, this
was supported by immunohistochemistry finding that
A2AR immunoreactivity was found to be colocated
with astrocytes (ie, GFAP elements). These results
suggest that the glial A2ARs are important components
for the A2AR modulation of neurodegeneration in the
MPTP model. However, the mechanisms underlying
this effect await further investigation. It should be
noted that such a nonneuronal-based cellular mecha-
nism for the A2AR-mediated control of neurodegenera-
tion provides an adequate rationale to understand the
broader neuroprotection afforded by A2AR inactivation
in diverse brain regions (with low A2AR density) and
against various brain injuries such as excitotoxicity, mi-
tochondrial toxicity, and ischemic brain injury.33,34
In conclusion, A2AR-mediated motor and neuropro-
tective effects are due to the presence of these receptors
on different cell types. A2ARs in forebrain neurons are
responsible for motor stimulation, and A2ARs in glial
cells are the likely culprits involved in the neuroprotec-
tive effects observed in the acute MPTP model of PD.
This identification of A2ARs in different cellular ele-
ments to control locomotion and neurodegeneration
opens the real possibility of targeting these two A2AR-
mediated functions in PD using different dose regi-
mens because A2AR antagonists exert neuroprotection
against ischemic and excitotoxic brain injuries at a dose
approximately 100-fold lower than its motor stimulant
doses.35,36
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